Humanized monoclonal antibody aiming at Japanese encephalitis virus and Zika virus and application thereof
By developing high-affinity human monoclonal antibodies, the problems of cumbersome detection and lack of treatment for Japanese encephalitis virus and Zika virus have been solved, achieving highly efficient neutralization of Japanese encephalitis virus and Zika virus, which is suitable for diagnosis and treatment.
Patent Information
- Application Number
- CN202411082946.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-08
AI Technical Summary
In the existing technology, the detection methods for Japanese encephalitis virus and Zika virus are cumbersome and prone to false negatives, and there is a lack of specific antiviral drugs, which makes diagnosis and treatment difficult.
A high-affinity human monoclonal antibody was developed that can specifically recognize and target the E protein of Japanese encephalitis virus and Zika virus, blocking their binding to cell surface receptors and demonstrating highly efficient virus neutralization ability.
This monoclonal antibody can effectively neutralize Japanese encephalitis virus and Zika virus, and is suitable for the diagnosis, prevention and treatment of related diseases, exhibiting broad-spectrum neutralizing activity.
Smart Images

Figure CN118930642A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the interdisciplinary field of immunology and molecular virology, and in particular to a humanized monoclonal antibody against Japanese encephalitis virus and Zika virus and an application thereof. Background Art
[0002] Insect-borne flaviviruses such as Japanese encephalitis virus (JEV) and Zika virus (ZIKV) that are transmitted by mosquito bites pose a serious threat to human health. The genome of these flaviviruses is approximately 11 kb and encodes three structural proteins (C, prM / M and E proteins). The E protein mediates viral infection by binding to sensitive cell surface receptors and is therefore a key viral antigen for inducing the production of neutralizing antibodies.
[0003] Currently, Japanese encephalitis virus is often detected by reverse transcriptase polymerase chain reaction (RT-PCR) test and serum / cerebrospinal fluid detection of IgM. Due to the short viremia period of Japanese encephalitis virus infection and the fact that the detection results are affected by other febrile diseases (such as dengue fever, malaria, leptospirosis and other arbovirus infections), the detection rate is low. At the same time, there is currently no specific antiviral drug or other treatment for Japanese encephalitis virus infection.
[0004] Currently, Zika virus detection is often confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) testing, but the clinical manifestations of Zika virus infection are similar to many febrile fevers (such as dengue fever, malaria, leptospirosis, and other arbovirus infections), and its geographical distribution is similar to other arboviruses. Therefore, the diagnosis of Zika virus infection requires laboratory confirmation by one of the following: 1) NAAT to detect viral RNA in serum or urine; 2) serological testing (enzyme-linked immunosorbent assay [ELISA] to detect IgM, plaque reduction neutralization test [PRNT] to detect Zika virus antibodies). This makes the existing detection technology more cumbersome. At the same time, the window period after Zika virus infection is extremely short, and the missed detection rate of RT-PCR is high. At the same time, there is currently no specific antiviral drug or other treatment for Zika virus infection.
[0005] Therefore, it is urgent to screen out monoclonal antibodies with high affinity and activity against Japanese encephalitis virus and Zika virus. Such antibodies are of great significance for protecting public life and health. Summary of the invention
[0006] The technical problem to be solved by the present invention is to provide a monoclonal antibody with high affinity and capable of simultaneously showing neutralizing activity against Japanese encephalitis and Zika virus.
[0007] To solve the above problems, the first aspect of the present invention provides a monoclonal antibody against Japanese encephalitis virus and Zika virus, wherein the monoclonal antibody comprises: a heavy chain variable region CDR1 shown in SEQ ID No.1, a heavy chain variable region CDR2 shown in SEQ ID No.2, a heavy chain variable region CDR3 shown in SEQ ID No.3, a light chain variable region CDR1 shown in SEQ ID No.4, a light chain variable region CDR2 shown in SEQ ID No.5, and a light chain variable region CDR3 shown in SEQ ID No.6.
[0008] The human monoclonal antibody provided by the present invention is a neutralizing antibody, which can specifically recognize and target the E protein of Japanese encephalitis virus and Zika virus, especially the extracellular region of the E protein, and can block the binding of the E protein to the cell surface receptor, showing the ability to efficiently neutralize the virus. Therefore, the antibody of the present invention is particularly suitable for diagnosing, preventing and treating diseases related to Japanese encephalitis virus and Zika virus infection (such as Japanese encephalitis and Zika fever).
[0009] Preferably, the monoclonal antibody further comprises a heavy chain variable region framework region FR1 as shown in SEQ ID No.7, a heavy chain variable region framework region FR2 as shown in SEQ ID No.8, a heavy chain variable region framework region FR3 as shown in SEQ ID No.9, a heavy chain variable region framework region FR4 as shown in SEQ ID No.10, a light chain variable region framework region FR1 as shown in SEQ ID No.11, a light chain variable region framework region FR2 as shown in SEQ ID No.12, a light chain variable region framework region FR3 as shown in SEQ ID No.13, and a light chain variable region framework region FR4 as shown in SEQ ID No.14.
[0010] In some preferred embodiments, the amino acid sequence of the heavy chain variable region of the monoclonal antibody provided by the present invention is shown as SEQ ID No.15, and the amino acid sequence of the light chain variable region is shown as SEQ ID No.16.
[0011] Preferably, the monoclonal antibody comprises: (a) a heavy chain variable region sequence having at least 90% sequence identity with the amino acid sequence shown in SEQ ID No. 15; (b) a heavy chain variable region sequence having at least 90% sequence identity with the amino acid sequence shown in SEQ ID No. 16; (c) The heavy chain variable region sequence as in (a) and the light chain variable region sequence as in (b).
[0012] In some preferred embodiments, the monoclonal antibody comprises: 1) a heavy chain variable region sequence having at least 95% sequence identity with the amino acid sequence shown in SEQ ID No. 15; 2) a heavy chain variable region sequence having at least 95% sequence identity with the amino acid sequence shown in SEQ ID No. 16; 3) The heavy chain variable region sequence in 1) and the light chain variable region sequence in 2).
[0013] Preferably, the monoclonal antibody further comprises a signal peptide sequence located at the N-terminus of the heavy chain variable region and / or a signal peptide sequence located at the N-terminus of the light chain variable region.
[0014] In some preferred embodiments, the signal peptide sequence located at the N-terminus of the heavy chain variable region is shown as SEQ ID No.19.
[0015] In some preferred embodiments, the signal peptide sequence located at the N-terminus of the light chain variable region is shown as SEQ ID No.20.
[0016] In some preferred embodiments, the antigen-binding fragment of the monoclonal antibody provided by the present invention is selected from any one or more of Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single-chain antibody (e.g., scFv), human antibody, chimeric antibody or bispecific or multispecific antibody.
[0017] In some preferred embodiments, the monoclonal antibody provided by the present invention further comprises a heavy chain constant region and a light chain constant region, wherein the amino acid sequence of the heavy chain constant region is shown in SEQ ID No.17, and the amino acid sequence of the light chain constant region is shown in SEQ ID No.18.
[0018] In some preferred embodiments, the light chain of the monoclonal antibody provided by the present invention is of κ type or λ type, preferably of κ type.
[0019] In some preferred embodiments, the monoclonal antibody or antigen-binding fragment thereof can specifically bind to the envelope protein (E protein) of Japanese encephalitis virus and Zika virus.
[0020] In some preferred embodiments, the monoclonal antibody or antigen-binding fragment thereof is capable of targeting the extracellular region of the E protein of Japanese encephalitis virus and Zika virus.
[0021] In some preferred embodiments, the monoclonal antibody or antigen-binding fragment thereof can inhibit receptor binding and / or membrane fusion processes mediated by the extracellular region of the E protein, thereby inhibiting viral infection of cells.
[0022] In some preferred embodiments, the monoclonal antibody or antigen-binding fragment thereof has neutralizing ability.
[0023] In some preferred embodiments, the monoclonal antibody or its antigen-binding fragment can inhibit Japanese encephalitis virus and Zika virus from infecting or entering host cells. Thus, the monoclonal antibody or its antigen-binding fragment can neutralize Japanese encephalitis virus and Zika virus, thereby achieving the purpose of preventing and treating infection by Japanese encephalitis virus and Zika virus.
[0024] Furthermore, the second aspect of the present invention provides a nucleic acid molecule for encoding the monoclonal antibody or antigen-binding fragment thereof according to the first aspect, the nucleic acid molecule comprising the nucleotide sequences shown in SEQ ID No. 21 and SEQ ID No. 22. Such nucleic acid molecules are not limited by the method of their production, and can be obtained by genetic engineering recombination technology or chemical synthesis methods.
[0025] In some preferred embodiments, the nucleic acid molecule includes a first polynucleotide comprising a nucleotide sequence encoding a signal peptide sequence, a nucleotide sequence capable of encoding a heavy chain variable region of the monoclonal antibody or antigen-binding fragment thereof of the present invention, and a nucleotide sequence capable of encoding a heavy chain constant region of the monoclonal antibody or antigen-binding fragment thereof of the present invention; and a second polynucleotide comprising a nucleotide sequence encoding a signal peptide sequence, a nucleotide sequence capable of encoding a light chain variable region of the monoclonal antibody or antigen-binding fragment thereof of the present invention, and a nucleotide sequence capable of encoding a light chain constant region of the monoclonal antibody or antigen-binding fragment thereof of the present invention.
[0026] In some preferred embodiments, the nucleic acid molecule further comprises a nucleotide sequence encoding a heavy chain constant region sequence. The heavy chain constant region of the monoclonal antibody provided by the present invention can be obtained by transcription and translation of the nucleotide sequence shown in SEQ ID No.23.
[0027] In some preferred embodiments, the nucleic acid molecule further comprises a nucleotide sequence encoding a light chain constant region sequence. The light chain constant region of the monoclonal antibody provided by the present invention can be obtained by transcription and translation of the nucleotide sequence shown in SEQ ID No.24.
[0028] In some preferred embodiments, the nucleic acid molecule further comprises a nucleotide sequence encoding a signal peptide sequence, which is located at the 5' end of the nucleotide sequence capable of encoding the heavy chain variable region of the monoclonal antibody of the present invention.
[0029] In some preferred embodiments, the signal peptide sequence located at the N-terminus of the heavy chain variable region can be obtained by transcription and translation of the nucleotide sequence shown in SEQ ID No.25.
[0030] In some preferred embodiments, the signal peptide sequence located at the N-terminus of the light chain variable region can be obtained by transcription and translation of the nucleotide sequence shown in SEQ ID No.26.
[0031] Furthermore, the third aspect of the present invention provides a vector, which comprises the nucleotide sequences shown in SEQ ID No.21 and SEQ ID No.22.
[0032] In some preferred embodiments, the vector provided by the present invention further comprises any one or more nucleic acid molecules of SEQ ID No. 23 to SEQ ID No. 26. The vector provided by the present invention can be a cloning vector or an expression vector.
[0033] In some preferred embodiments, the vector of the present invention is, for example, a plasmid, a cosmid, a phage, and the like.
[0034] Furthermore, the fourth aspect of the present invention provides a host cell, wherein the host cell contains the nucleic acid molecule described in the second aspect or the vector described in the third aspect, and the host cell is a prokaryotic cell or a eukaryotic cell.
[0035] In some preferred embodiments, the host cell is a prokaryotic cell or a eukaryotic cell. More preferably, the host cell is selected from Escherichia coli cells, yeast cells, insect cells, plant cells, mammalian cells, mouse cells, and human cells. The cell of the present invention may also be a cell line, such as 293T cells.
[0036] In some preferred embodiments, the present invention also provides a method for preparing the monoclonal antibody or antigen-binding fragment thereof of the present invention, which comprises culturing the host cell of the present invention under suitable conditions, and recovering the monoclonal antibody or antigen-binding fragment thereof of the present invention from the cell culture.
[0037] Furthermore, the fifth aspect of the present invention provides a pharmaceutical composition, comprising: (i) any one of the monoclonal antibody according to any one of claims 1 to 4, the nucleic acid molecule according to claim 5, the vector according to claim 6, and the host cell according to claim 7; and (ii) pharmaceutically acceptable carriers and / or excipients.
[0038] Further preferably, the pharmaceutical composition further comprises other pharmaceutically active agents, such as ribavirin.
[0039] In some preferred embodiments, the pharmaceutical composition may be a diagnostic agent or a therapeutic agent.
[0040] Furthermore, the sixth aspect of the present invention provides an application, specifically comprising: 1) Use of the monoclonal antibody described in the first aspect in the preparation of diagnostic products for Japanese encephalitis virus and / or Zika virus infection; 2) Use of the monoclonal antibody described in the first aspect in the preparation of a drug for treating Japanese encephalitis virus and / or Zika virus infection; 3) Use of the nucleic acid molecule described in the second aspect in the preparation of a drug for treating Japanese encephalitis virus and / or Zika virus infection; 5) Use of the vector described in the third aspect in the preparation of a drug for treating Japanese encephalitis virus and / or Zika virus infection; 6) Use of the host cell of the fourth aspect in the preparation of a drug for treating Japanese encephalitis virus and / or Zika virus infection; 7) Use of the pharmaceutical composition of the fifth aspect in the preparation of a medicament for treating Japanese encephalitis virus and / or Zika virus infection.
[0041] In some preferred embodiments, the monoclonal antibodies or antigen-binding fragments thereof provided by the present invention further comprise a detectable label.
[0042] In some preferred embodiments, the aforementioned kit further comprises a second antibody that specifically recognizes the monoclonal antibody or antigen-binding fragment thereof or anti-idiotypic antibody of the present invention. Preferably, the second antibody further comprises a detectable label. Such detectable labels are well known to those skilled in the art, including but not limited to radioisotopes, fluorescent substances, luminescent substances, colored substances and enzymes (e.g., horseradish peroxidase), etc.
[0043] Further preferably, the present invention provides a method for detecting the presence or level of Japanese encephalitis virus, Zika virus or its E protein or the extracellular region of E protein in a sample, comprising using a monoclonal antibody or its antigen-binding fragment of the present invention. In certain preferred embodiments, the monoclonal antibody or its antigen-binding fragment of the present invention further comprises a detectable label. In another preferred embodiment, the method further comprises detecting the monoclonal antibody or its antigen-binding fragment of the present invention using a second antibody carrying a detectable label. The method can be used for diagnostic purposes (e.g., the sample is a sample from a patient), or non-diagnostic purposes (e.g., the sample is a cell sample, not a sample from a patient).
[0044] Further preferably, the present invention provides a method for diagnosing whether a subject is infected with Japanese encephalitis virus or Zika virus, comprising: using the monoclonal antibody or antigen-binding fragment thereof of the present invention to detect the presence of Japanese encephalitis virus, Zika virus or its E protein or the extracellular region of the E protein in a sample from the subject. In certain preferred embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention further comprises a detectable marker. In another preferred embodiment, the method further comprises detecting the monoclonal antibody or antigen-binding fragment thereof or anti-idiotypic antibody of the present invention using a second antibody carrying a detectable marker.
[0045] Further preferably, the present invention provides use of the monoclonal antibody or antigen-binding fragment thereof of the first aspect in preparing a product, such as a kit for detecting the presence or level of Japanese encephalitis virus, Zika virus or its E protein or the extracellular region of the E protein in a sample, or for diagnosing whether a subject is infected with Japanese encephalitis virus or Zika virus.
[0046] In some preferred embodiments, the sample includes but is not limited to excrement, oral or nasal secretions, alveolar lavage fluid, etc. from a subject (e.g., a mammal, preferably a human). The general method of using a monoclonal antibody or its antigen-binding fragment to detect the presence or level of a target virus or antigen (e.g., Japanese encephalitis virus, Zika virus, or its E protein or the extracellular region of the E protein) in a sample is well known to those skilled in the art. In certain preferred embodiments, the detection method can use enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay, chemiluminescent immunoassay, radioimmunoassay, fluorescent immunoassay, immunochromatography, competitive method, and similar detection methods.
[0047] Further preferably, the present invention provides a method for neutralizing the toxicity of Japanese encephalitis virus and Zika virus in a sample, comprising contacting a sample containing Japanese encephalitis virus and Zika virus with a monoclonal antibody or an antigen-binding fragment thereof of the present invention. Such methods can be used for therapeutic purposes, or non-therapeutic purposes (e.g., the sample is a cell sample, not a patient or a sample from a patient).
[0048] Further preferably, the present invention provides the use of the monoclonal antibody or its antigen-binding fragment provided in the first aspect for preparing a drug, wherein the drug is used to neutralize the virulence of Japanese encephalitis virus and Zika virus in a sample. In another aspect, the present invention provides the monoclonal antibody or its antigen-binding fragment as described above, which is used to neutralize the virulence of Japanese encephalitis virus and Zika virus in a sample.
[0049] Further preferably, the present invention provides use of the monoclonal antibody or antigen-binding fragment thereof provided in the first aspect in preparing a pharmaceutical composition, wherein the pharmaceutical composition is used to prevent or treat Japanese encephalitis virus, Zika virus infection or diseases associated with these viral infections (e.g., Japanese encephalitis, Zika fever) in a subject.
[0050] Further preferably, the present invention provides a monoclonal antibody or an antigen-binding fragment thereof as described above, which is used to prevent or treat Japanese encephalitis virus, Zika virus infection or diseases associated with these viral infections (eg, Japanese encephalitis, Zika fever) in a subject.
[0051] Compared with the prior art, the present invention has the following beneficial effects: the monoclonal antibody provided by the present invention can bind to the extracellular region of the E protein of Japanese encephalitis virus and Zika virus with high affinity, and has strong neutralizing activity against Japanese encephalitis virus and Zika virus. Specifically, the monoclonal antibody provided by the present invention has a high affinity for the extracellular region of the E protein of Japanese encephalitis virus and Zika virus, and the neutralization titer data (half-inhibitory concentration, IC 50 Therefore, as a broad-spectrum neutralizing antibody, the monoclonal antibody of the present invention has an ideal clinical application value for preventing and treating Japanese encephalitis virus and Zika virus infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 This is the WB test result of the monoclonal antibody LZY3412 expressed in Example 4 of the specific embodiment of the present invention; Figure 2 The kinetic curve results of different concentrations of LZY3412 monoclonal antibody binding to the extracellular region of E protein of Japanese encephalitis virus (JEV-E406) and the extracellular region of E protein of Zika virus (ZIKV-E410) in Example 5 of the specific embodiment of the present invention; Figure 3 This is a graph showing the results of the in vitro neutralization activity test of LZY3412 monoclonal antibody at different concentrations against Japanese encephalitis virus and Zika virus in Example 6 of the specific embodiment of the present invention; Figure 4 This is a graph showing the results of a survival experiment in which different doses of LZY3412 monoclonal antibody protected mice against lethal Japanese encephalitis virus and Zika virus attacks in Example 7 of the specific embodiment of the present invention. DETAILED DESCRIPTION
[0053] In order to make the above-mentioned purposes, features and advantages of the present invention more obvious and easy to understand, the specific embodiments of the present invention are described in detail below. It should be noted that the following embodiments are only used to illustrate the implementation method and typical parameters of the present invention, and are not used to limit the parameter range described in the present invention. Reasonable changes derived therefrom are still within the scope of protection of the claims of the present invention.
[0054] It should be noted that the endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, and these numerical ranges should be regarded as specifically disclosed in this article.
[0055] Unless otherwise defined, all terms, symbols and other scientific terms used herein are intended to have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. In some cases, terms with conventionally understood meanings are defined herein for the purpose of clarification or ease of reference, and such definitions herein should not be construed as indicating significant differences from conventional understandings in the art. The technical methods described or cited herein are generally well understood by those skilled in the art and are adopted by conventional methods. Unless otherwise stated, the use of commercially available kits, reagents and instruments is carried out in accordance with the protocols and parameters given by the manufacturer.
[0056] Terminology Note: Antibody: An immunoglobulin molecule composed of two pairs of polypeptide chains, each pair having one "light" (L) chain and one "heavy" (H) chain. Antibody light chains can be classified as kappa and lambda light chains. Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, which defines antibodies into five classes: IgM, IgD, IgG, IgA, and IgE. Within the light and heavy chains, the variable and constant regions are connected by a "J" region of about 12 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The constant region of an antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. VH and VL regions can also be subdivided into highly variable regions [called complementary determining regions (CDRs)], interspersed with more conservative regions called framework regions (FRs). Each VH and VL has seven parts arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions (VH and VL) of each heavy chain / light chain pair form antibody binding sites, respectively. The allocation of amino acids to each region or domain follows the Kabat Sequences of Proteins of Immunological Interest [NationalInstitutes of Health, Bethesda, Md. (1987 and 1991)], or the definition of Chothia et al. (1989, Nature. 342:878-883). The term "antibody" is not limited to any particular method for producing antibodies. For example, it includes recombinant antibodies, monoclonal antibodies, and polyclonal antibodies. The antibodies can be of different isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibodies.
[0057] Antigen binding fragment: refers to a polypeptide comprising a fragment of a full-length antibody, which retains the ability to specifically bind to the same antigen bound by the full-length antibody, and / or competes with the full-length antibody for specific binding to the antigen, which is also referred to as an "antigen binding portion". See generally, Fundamental Immunology, Ch. 7 [Paul, W., ed., 2nd edition, Raven Press, NY (1989)], which is incorporated herein by reference in its entirety for all purposes. Antigen binding fragments of antibodies can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of intact antibodies. In some cases, antigen binding fragments include Fab, Fab', F(ab')2, Fd, Fv, dAb and complementary determining region (CDR) fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies (diabody, dAb) and such polypeptides, which contain at least a portion of an antibody sufficient to confer specific antigen binding ability to a polypeptide. In some cases, the antigen-binding fragment of an antibody is a single-chain antibody (e.g., scFv), in which the VL and VH domains are paired to form a monovalent molecule by a linker that enables them to be produced as a single polypeptide chain [see, e.g., Bird et al., 1988, Science. 242:423-426. and Huston et al., 1988, Proc. Natl. Acad. Sci. USA. 85:5879-5883.]. Such scFv molecules may have a general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof. For example, a linker having an amino acid sequence (GGGGS) 4 may be used, but variants thereof may also be used (Holliger et al., 1993, Proc. Natl. Acad. Sci. USA. 90: 6444-6448.). Other linkers useful in the present invention are described by Alfthan et al., 1995, Protein Eng. 8:725-731. Choi et al., 2001, Eur. J. Immunol. 31: 94-106.In some cases, the antigen-binding fragment of an antibody is a diabody, i.e., a bivalent antibody in which the VH and VL domains are expressed on a single polypeptide chain, but a linker that is too short to allow pairing between the two domains of the same chain is used, thereby forcing the domains to pair with the complementary domains of another chain and create two antigen-binding sites [see, e.g., Holliger P. et al., 1993, Proc. Natl. Acad. Sci. USA .90:6444 6448. and Poljak RJ et al., 1994, Structure. 2:1121-1123. Antibody antigen-binding fragments (e.g., the above-mentioned antibody fragments) can be obtained from a given antibody (e.g., monoclonal antibody LZY3412 provided by the present invention) using conventional techniques known to those skilled in the art (e.g., recombinant DNA technology or enzymatic or chemical cleavage methods), and the antigen-binding fragments of the antibody can be screened for specificity in the same manner as for intact antibodies. In the present invention, unless the context clearly indicates otherwise, when the term "antibody" is mentioned, it includes not only intact antibodies but also antigen-binding fragments of antibodies.
[0058] Monoclonal antibody: an antibody or a fragment of an antibody from a group of highly homologous antibody molecules, that is, a group of identical antibody molecules except for natural mutations that may occur spontaneously. Monoclonal antibodies have high specificity for a single epitope on an antigen. Polyclonal antibodies are relative to monoclonal antibodies, and they usually contain at least 2 or more different antibodies, which usually recognize different epitopes on an antigen. Monoclonal antibodies can usually be obtained using the hybridoma technology first reported by Kohler et al. (1975, Nature. 256: 495), but can also be obtained using recombinant DNA technology [see Journal of virological methods, 2009. 158 (1-2): 171-179]. As used in the present invention, "neutralizing antibodies" refer to antibodies or antibody fragments that can eliminate or significantly reduce the virulence of the target virus (e.g., the ability to infect cells).
[0059] Vector: A nucleic acid carrier into which a polynucleotide can be inserted. When a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art, and include but are not limited to: plasmids; phagemids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC); bacteriophages such as lambda phage or M13 phage and animal viruses. Animal viruses that can be used as vectors include but are not limited to retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses (such as SV40). A vector can contain a variety of elements that control expression, including but not limited to promoter sequences, transcription start sequences, enhancer sequences, selection elements and reporter genes. In addition, the vector may also contain a replication start site.
[0060] Host cells: cells that can be used to introduce vectors, including but not limited to prokaryotic cells such as Escherichia coli, fungal cells such as yeast cells, insect cells such as S2 Drosophila cells, animal cells such as CHO cells, or human cells such as HEK293 cells.
[0061] Specific binding: A non-random binding reaction between two molecules, such as the reaction between an antibody and the antigen to which it is directed. In certain embodiments, an antibody that specifically binds to an antigen (or has specificity for an antigen) means that the antibody binds to the antigen with a specificity of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 The dissociation equilibrium (KD) of M or less usually binds to the antigen.
[0062] KD: refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding ability between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen. Generally, antibodies (e.g., monoclonal antibody LZY3412 of the present invention) have a KD of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10The PCR products bind to antigens (e.g., E protein of Japanese encephalitis virus and Zika virus) with a dissociation equilibrium constant (KD) of 2 M or less, as determined using surface plasmon resonance (SPR) in a BIACORE 8K instrument.
[0063] Neutralizing activity: refers to the functional activity of antibodies or antibody fragments that bind to antigenic proteins on the virus, thereby preventing the virus from infecting cells and / or the maturation of viral progeny and / or the release of viral progeny. Antibodies or antibody fragments with neutralizing activity can prevent the multiplication of the virus, thereby inhibiting or eliminating viral infection.
[0064] Japanese encephalitis virus: refers to the Japanese encephalitis virus (JEV), which is officially classified by the International Committee on Taxonomy of Viruses (ICTV). The two have the same meaning and can be used interchangeably.
[0065] Japanese encephalitis and Japanese encephalitis: refer to encephalitis caused by JEV infection; the two have the same meaning and can be used interchangeably.
[0066] Zika fever: refers to a fever-related disease caused by ZIKV infection. The two terms have the same meaning and can be used interchangeably.
[0067] As described in the background technology, at present, for Japanese encephalitis virus infection and Zika virus infection, there are technical defects such as high detection missed detection rate and no specific medicine for these viruses. To solve the above problems, the specific embodiments of the present invention provide a monoclonal antibody for Japanese encephalitis virus and Zika virus, which can specifically recognize and target the E protein of Japanese encephalitis virus and Zika virus, especially the extracellular region of E protein, and can block the binding of E protein to cell surface receptors, showing the ability of efficient neutralization of viruses. Therefore, the antibody of the present invention is particularly suitable for diagnosing, preventing and treating diseases related to Japanese encephalitis virus and Zika virus infection (such as Japanese encephalitis and Zika fever).
[0068] Specifically, the monoclonal antibody provided in a specific embodiment of the present invention includes: a heavy chain variable region CDR1 (VH-CDR1) shown in SEQ ID No.1, a heavy chain variable region CDR2 (VH-CDR2) shown in SEQ ID No.2, a heavy chain variable region CDR3 (VH-CDR3) shown in SEQ ID No.3, a light chain variable region CDR1 (VL-CDR1) shown in SEQ ID No.4, a light chain variable region CDR2 (VL-CDR2) shown in SEQ ID No.5, and a light chain variable region CDR3 (VL-CDR3) shown in SEQ ID No.6.
[0069] The monoclonal antibody provided in the above embodiment also includes the heavy chain variable region framework region FR1 (VH-FR1) shown in SEQ ID No.7, the heavy chain variable region framework region FR2 (VH-FR2) shown in SEQ ID No.8, the heavy chain variable region framework region FR3 (VH-FR3) shown in SEQ ID No.9, the heavy chain variable region framework region FR4 (VH-FR4) shown in SEQ ID No.10, the light chain variable region framework region FR1 (VL-FR1) shown in SEQ ID No.11, the light chain variable region framework region FR2 (VL-FR2) shown in SEQ ID No.12, the light chain variable region framework region FR3 (VL-FR3) shown in SEQ ID No.13, and the light chain variable region framework region FR4 (VL-FR4) shown in SEQ ID No.14.
[0070] Specifically, in the above embodiment, the amino acid sequence of the heavy chain variable region (VH) of the monoclonal antibody provided by the present invention is shown as SEQ ID No.15, and the amino acid sequence of the light chain variable region (VL) is shown as SEQ ID No.16.
[0071] More specifically, the amino acid sequence of the heavy chain constant region (CH) of the monoclonal antibody provided by the present invention is shown in SEQ ID No.17; the amino acid sequence of the light chain constant region (CL) is shown in SEQ ID No.18.
[0072] More specifically, in the above embodiment, the monoclonal antibody provided by the present invention should include: (a) a heavy chain variable region sequence having at least 90% sequence identity with the amino acid sequence shown in SEQ ID No. 15; (b) a heavy chain variable region sequence having at least 90% sequence identity with the amino acid sequence shown in SEQ ID No. 16; (c) The heavy chain variable region sequence as in (a) and the light chain variable region sequence as in (b).
[0073] In the above embodiment, the monoclonal antibody further comprises a signal peptide sequence located at the N-terminus of the heavy chain variable region and / or a signal peptide sequence located at the N-terminus of the light chain variable region.
[0074] More specifically, the signal peptide sequence at the N-terminus of the heavy chain variable region is preferably as shown in SEQ ID No.19; the signal peptide sequence at the N-terminus of the light chain variable region is preferably as shown in SEQ ID No.20.
[0075] A specific embodiment of the present invention further provides a nucleic acid molecule, which is used to encode the aforementioned monoclonal antibody or its antigen-binding fragment, and should include nucleotide sequences preferably shown as SEQ ID No.21 and SEQ ID No.22.
[0076] More specifically, the nucleic acid molecule further comprises a nucleotide sequence as shown in SEQ ID No. 23 encoding a heavy chain constant region and a nucleotide sequence as shown in SEQ ID No. 24 encoding a light chain constant region.
[0077] More specifically, the nucleic acid molecule also includes a nucleotide sequence as shown in SEQ ID No. 25 encoding a signal peptide at the N-terminus of the heavy chain variable region and a nucleotide sequence as shown in SEQ ID No. 26 encoding a signal peptide at the N-terminus of the light chain variable region.
[0078] A specific embodiment of the present invention further provides a vector comprising the nucleotide sequences shown in SEQ ID No.21 and SEQ ID No.22.
[0079] More specifically, the vector also includes any one or more nucleic acid molecules of SEQ ID No.23 to SEQ ID No.26.
[0080] A specific embodiment of the present invention further provides a host cell, which is a prokaryotic cell or a eukaryotic cell.
[0081] The technical solution of the present invention is further described below through specific embodiments.
[0082] The specific implementation method of the present invention first uses the extracellular region (E410) of Zika virus E protein expressed by Escherichia coli as an antigen, and screens memory B cells that can specifically bind to ZIKV-E410 from peripheral blood mononuclear cells (PBMCs) of healthy adult volunteers (22 years old) vaccinated with Japanese encephalitis virus attenuated vaccine by flow cytometry, and then performs BCR 10Genomics sequencing on the single B cells obtained by screening to obtain the gene sequence encoding the variable region of the antibody in the single B cell. Further, the sequence encoding the variable region of the antibody is connected to the constant region gene into an expression vector, and expressed and purified in mammalian cells to obtain the monoclonal antibody LZY3412. A series of functional tests were performed on monoclonal antibody LZY3412, and the results showed that monoclonal antibody LZY3412 can specifically bind to JEV-E406 and ZIKV-E410, inhibit the infection of Vero cells by Japanese encephalitis virus and Zika virus, protect mice against lethal Japanese encephalitis virus and Zika virus attacks, and has broad-spectrum neutralizing activity against Japanese encephalitis virus and Zika virus infections.
[0083] Example 1 Expression and purification of the extracellular domain of E protein of Japanese encephalitis virus and Zika virus The coding sequences of JEV-E406 (residues 1-406, GenBank accession no: MK558811) and ZIKV-E410 (residues 1-410, GenBank accession no: KX117076.1) with six His tags at the C-terminus after E. coli codon optimization were cloned into the prokaryotic expression vector pET21a. The amino acid sequence of JEV-406 is shown in SEQ ID No. 27, and the amino acid sequence of ZIKV-E410 is shown in SEQ ID No. 28.
[0084] The recombinant plasmids pET21a-JEV-E406 and pET21a-ZIKV-E410 were transformed into Escherichia coli BL21 strain and IPTG was used to induce protein expression.
[0085] The JEV-E406 and ZIKV-E410 proteins were separated and purified by Ni-NTA affinity chromatography. The purity of the two proteins was detected by SDS-PAGE and WB experiments.
[0086] Example 2 Isolation of memory B cells that specifically recognize ZIKV-E410 protein With the informed consent of healthy volunteers who received JEV live attenuated vaccine, 100 ml of peripheral venous blood was collected and peripheral blood mononuclear cells (PBMCs) were separated using human lymphocyte separation medium.
[0087] The separated PBMCs were mixed with a biotinylated antibody mixture (containing biotinylated anti-human CD2 monoclonal antibody, anti-human CD3 monoclonal antibody, anti-human CD14 monoclonal antibody, anti-human CD43 monoclonal antibody, anti-human CD56 monoclonal antibody, and anti-human CD235a monoclonal antibody) in a flow cytometry tube and incubated at 4°C for 30 min. Add pre-cooled buffer (0.5% BSA / PBS, containing 20 mM EDTA), add Anti-biotin microbeads, and incubate at 4°C for 30 min; add pre-cooled buffer (0.5% BSA / PBS, containing 20 mM EDTA), centrifuge at 2000 rpm for 10 min, and discard the supernatant; add pre-cooled buffer (0.5% BSA / PBS, containing 20 mM EDTA) to suspend the cell pellet, transfer to a flow tube, insert a magnet and wait for 3 min, collect the unadsorbed cells, use pre-cooled buffer (0.5% BSA / PBS, containing 20mM EDTA) to wash the adsorbed magnetic beads, insert a magnet and wait for 3 min, collect the unadsorbed cells; transfer all unadsorbed cell fluids to a 15 ml centrifuge tube; centrifuge at 2000 rpm for 10 min, discard the supernatant, and use pre-cooled buffer (0.5% BSA / PBS, containing 20mM EDTA) to suspend the cell (memory B cell) pellet.
[0088] Take 5 ml magnetic beads (1 μm diameter) and add them to the flow tube, insert the magnet and wait for 3 min, and discard the supernatant; add 4 ml PBS to suspend the magnetic beads, insert the magnet and wait for 3 min, and discard the supernatant; add 4 ml 5 μM imidazole solution, insert the magnet and wait for 3 min, and discard the supernatant; add protein solution (2 mg ZIKV-E410) and appropriate amount of binding buffer to 4 ml, tighten the lid and shake on a shaker for 40 min; insert the magnet and wait for 3 min, discard the supernatant, add 4 ml PBS to suspend the magnetic beads, insert the magnet and wait for 3 min, and discard the supernatant; add 4 ml 5% BSA / PBS to suspend the magnetic beads, and shake on a shaker for 10 min; insert the magnet and wait for 3 min, discard the supernatant, add 4 ml PBS to suspend the magnetic beads, insert the magnet and wait for 3 min, and discard the supernatant; suspend the above magnetic beads with 1 ml memory B cell suspension (isolated from 100 ml peripheral venous blood), shake on a shaker for 20 min; insert the magnet and wait for 3 min, and discard the unbound solution; add 4 ml pre-cooled buffer to suspend the magnetic beads, insert the magnet and wait for 3 min, discard the unbound solution, and add pre-cooled buffer to wash off the adsorbed cells (i.e., target cells); The above cells were subjected to 10× single-cell expression profiling sequencing + BCR library construction sequencing and analysis.
[0089] Example 3 Isolation and identification of LZY3412 monoclonal antibody and construction of recombinant expression vector A total of more than 6,000 genes of the V region of the BCR of memory B cells were measured. Through sequence analysis, the variable region (V region) sequences of the light chain and heavy chain of a strain named LZY3412 monoclonal antibody were selected for subsequent research. The amino acid sequence of the heavy chain variable region of LZY3412 monoclonal antibody is shown in SEQ ID No.15 (the encoding gene is shown in SEQ ID No.21), the CDR1 of the heavy chain variable region has the amino acid sequence shown in SEQ ID No.1, CDR2 has the amino acid sequence shown in SEQ ID No.2, and CDR3 has the amino acid sequence shown in SEQ ID No.3. The amino acid sequence of the light chain variable region is shown in SEQ ID No.16 (the encoding gene is shown in SEQ ID No.22), the CDR1 of the light chain variable region has the amino acid sequence shown in SEQ ID No.4, CDR2 has the amino acid sequence shown in SEQ ID No.5, and CDR3 has the amino acid sequence shown in SEQ ID No.6. The V region genes of the heavy chain and light chain of LZY3412 monoclonal antibody are shown in Tables 1 and 2.
[0090] Table 1 LZY3412 monoclonal antibody heavy chain V region gene VH alleles JH allele LZY3412 IGHV4-39 IGHJ6 Table 2 LZY3412 monoclonal antibody light chain V region gene VL allele JL allele LZY3412 IGKV1D-39 IGKJ1 The nucleotide sequences encoding the LZY3412 heavy chain / light chain variable regions obtained by analysis were synthesized and cloned into the expression vector pCAGGS containing the nucleotide sequences encoding the heavy chain / κ chain constant regions, thereby obtaining recombinant expression vectors encoding the LZY3412 monoclonal antibody heavy chain and light chain, respectively. The construction method of the constructs expressing the heavy chain and light chain is as follows:
[0091] Heavy chain coding sequence (5'-3'): CMV promoter-EcoR I restriction site-signal peptide sequence gene-VH gene-CH gene-Xho I restriction site; Light chain (κ) coding sequence (5'-3'): CMV promoter - EcoR I restriction site - signal peptide sequence gene - VL gene - CL (κ) gene - Xho I restriction site; Among them, the amino acid sequence of the signal peptide sequence is shown in SED ID No.19 (the encoding gene is shown in SEQ ID No.25), the amino acid sequence of CH is shown in SED ID No.17 (the encoding gene is shown in SEQ ID No.23), and the amino acid sequence of CL is shown in SED ID No.18 (the encoding gene is shown in SEQ ID No.24).
[0092] Example 4 Heavy chain and light chain plasmids (recombinant expression vectors pCAGGS-LZY3412H and pCAGGS-LZY3412L encoding the heavy chain and light chain of LZY3412 monoclonal antibody respectively obtained in Example 3) were co-transfected into 293T cells. The weight ratio of heavy chain plasmid pCAGGS-LZY3412H to light chain plasmid pCAGGS-LZY3412L was 1.07:0.93, and 20 μg of plasmid (heavy chain plasmid + light chain plasmid) and 40 μg of PEI were transfected into each cell dish (10 cm in diameter) of 293T cells. Cell supernatants were collected 48 h and 96 h after transfection and filtered with a 0.22 μm syringe filter, and then purified using a Pierce protein A / G agarose column (Thermo Fisher), and the monoclonal antibody was concentrated using a 50 kDa molecular weight cutoff ultrafiltration tube (Millipore). Then, the samples were run through SDS-PAGE (under reducing and non-reducing conditions), transferred to membranes, and subjected to WB experiments. Figure 1 As shown, "M" on the gel image indicates protein marker; "No DTT" indicates that DTT was not added (non-reducing SDS-PAGE), and "DTT" indicates that DTT was added (reducing SDS-PAGE); "Anti-human IgG L chain" indicates that the detection antibody is HRP-labeled anti-human IgG light chain monoclonal antibody when doing WB, and "Anti-human IgG H chain" indicates that the detection antibody is HRP-labeled anti-human IgG heavy chain monoclonal antibody when doing WB. The results show that purified LZY3412 monoclonal antibody was obtained.
[0093] Example 5 Evaluation of the binding ability of LZY3412 mAb to JEV-E406 and ZIKV-E410 In this example, the surface plasmon resonance analysis was performed using LifeDiscTM MetaSPR chip (Quantum Precision [Hangzhou] Biotechnology Co., Ltd.). The specific steps are as follows:
[0094] First, JEV-E406 or ZIKV-E410 (20 μg / ml) was immobilized on the LifeDiscTM MetaSPR chip (Quantum Precision [Hangzhou] Biotechnology Co., Ltd.), and then LZY3412 serially diluted with pH 7.4 PBST solution was sequentially passed through each channel (40, 80, 160, 320 μg / ml [i.e., 0.267 μM, 0.534 μM, 1.068 μM, 2.136 μM] were loaded one by one). The kinetic curves of LZY3412 binding to JEV-E406 or ZIKV-E410 protein were recorded ( Figure 2The kinetic constants (as shown in Table 3) were calculated using WeSPR One software (Quantum Precision Biotechnology Co., Ltd., Hangzhou) and fitted in the “1:1 binding” mode. Figure 2 The results in Table 3 show that LZY3412 monoclonal antibody can bind to the extracellular region of the E protein of JEV and ZIKV (JEV-E406 and ZIKV-E410) with high affinity. The amino acid sequence of JEV-406 is shown in SEQ ID No. 27, and the amino acid sequence of ZIKV-E410 is shown in SEQ ID No. 28.
[0095] Table 3 Affinity of LZY3412 mAb to JEV-E406 and ZIKV-E410 antigen Affinity KD (nM) JEV-E406 440 ± 16 ZIKV-E410 482.5 ± 91.5 Example 6 Neutralization of JEV and ZIKV by LZY3412 monoclonal antibody in vitro Vero cells were plated in 24-well plates (1 × 10 5 / well) and cultured for 24 h.
[0096] The LZY3412 monoclonal antibody to be tested was diluted 3-fold (starting from 3.67 μg / ml) in a 96-well plate, and the virus to be tested (JEV or ZIKV, 50 viral plaque-forming units (PFU) / well) was added to each well and incubated at 37°C for 1 h.
[0097] The Vero cell supernatant was discarded, and the virus / monoclonal antibody mixture was added to the cells and infected at 37°C for 1.5 h.
[0098] The virus solution was discarded, and 1% methylcellulose culture medium was added to each well to cover the cells and cultured for 3-6 days.
[0099] Add 4% paraformaldehyde to each well for fixation at room temperature for 1 h, and then wash the plate.
[0100] Each well was stained with 0.5% crystal violet staining solution at room temperature for 10 min, and the plate was washed.
[0101] Count the number of virus plaques in each well and calculate the neutralization titer (half inhibitory concentration, IC) of the diluted monoclonal antibody against each virus. 50 value).
[0102] IC 50 GraphPad Prism 6 software was used for analysis. The analysis results are shown in Tables 4 and Figure 3 It can be seen that LZY3412 monoclonal antibody can inhibit JEV and ZIKV with extremely high neutralizing activity.
[0103] Table 4 Neutralization titers (half inhibitory concentration, IC) of LZY3412 monoclonal antibody against JEV and ZIKV 50 ) Virus <![CDATA[Half inhibitory concentration, IC 50 (ng / ml)]]> JEV 35.7 ± 4.1 ZGar 2211 ± 951.5 Example 7 Experiment on the protection of mice against lethal JEV or ZIKV challenge by LZY3412 monoclonal antibody JEV (10 PFU) or ZIKV (1000 PFU) was injected subcutaneously into the back of 1-day-old C57BL / 6 mice; After 2 hours, 1 or 10 μg of LZY3412 monoclonal antibody was injected subcutaneously into the back of mice for a mouse survival experiment (mouse body weight and mortality were recorded daily).
[0104] Prism 6 was used to analyze, count and plot the data. Figure 4 As shown, after JEV infection, the percentage survival rate of mice given 1 μg or 10 μg of LZY3412 mAb was significantly higher than that of mice not given LZY3412 mAb (33.3% versus 7.7%, P=0.0196; 50% versus 8.3%, P=0.0444, respectively); after ZIKV infection, the percentage survival rate of mice given 1 μg or 10 μg of LZY3412 mAb was significantly higher than that of mice not given LZY3412 mAb (28.6% versus 0, P=0.0329; 50% versus 0, P=0.0011, respectively).
[0105] Although the disclosure is disclosed as above, the protection scope of the disclosure is not limited thereto. Those skilled in the art can make various changes and modifications without departing from the spirit and scope of the disclosure, and these changes and modifications will fall within the protection scope of the present invention.
Claims
1. A human monoclonal antibody against Japanese encephalitis virus and Zika virus, characterized in that: The monoclonal antibody comprises: a heavy chain variable region CDR1 as shown in SEQ ID No.1, a heavy chain variable region CDR2 as shown in SEQ ID No.2, a heavy chain variable region CDR3 as shown in SEQ ID No.3, a light chain variable region CDR1 as shown in SEQ ID No.4, a light chain variable region CDR2 as shown in SEQ ID No.5, and a light chain variable region CDR3 as shown in SEQ ID No.
6.
2. The monoclonal antibody according to claim 1, characterized in that The monoclonal antibody further includes a heavy chain variable region framework region FR1 as shown in SEQ ID No.7, a heavy chain variable region framework region FR2 as shown in SEQ ID No.8, a heavy chain variable region framework region FR3 as shown in SEQ ID No.9, a heavy chain variable region framework region FR4 as shown in SEQ ID No.10, a light chain variable region framework region FR1 as shown in SEQ ID No.11, a light chain variable region framework region FR2 as shown in SEQ ID No.12, a light chain variable region framework region FR3 as shown in SEQ ID No.13, and a light chain variable region framework region FR4 as shown in SEQ ID No.
14.
3. The monoclonal antibody according to claim 1, characterized in that The monoclonal antibodies include: (a) a heavy chain variable region sequence having at least 90% sequence identity with the amino acid sequence shown in SEQ ID No. 15; (b) a heavy chain variable region sequence having at least 90% sequence identity with the amino acid sequence shown in SEQ ID No. 16; (c) The heavy chain variable region sequence as in (a) and the light chain variable region sequence as in (b).
4. The monoclonal antibody according to claim 1, characterized in that The monoclonal antibody further comprises a signal peptide sequence located at the N-terminus of the heavy chain variable region and / or a signal peptide sequence located at the N-terminus of the light chain variable region.
5. A nucleic acid molecule, characterized in that The nucleic acid molecule is used to encode the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, and the nucleic acid molecule includes the nucleotide sequences shown in SEQ ID No. 21 and SEQ ID No.
22.
6. A carrier, characterized in that The vector comprises the nucleotide sequences shown in SEQ ID No.21 and SEQ ID No.
22.
7. A host cell, characterized in that The host cell contains the nucleic acid molecule according to claim 5 or the vector according to claim 6, and the host cell is a prokaryotic cell or a eukaryotic cell.
8. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises: (i) any one of the monoclonal antibody according to any one of claims 1 to 4, the nucleic acid molecule according to claim 5, the vector according to claim 6, and the host cell according to claim 7; and (ii) pharmaceutically acceptable carriers and / or excipients.
9. An application, characterized in that: include: Use of the monoclonal antibody according to any one of claims 1 to 4 in the preparation of a diagnostic product for Japanese encephalitis virus and / or Zika virus infection; Use of the monoclonal antibody according to any one of claims 1 to 4 in the preparation of a medicament for treating Japanese encephalitis virus and / or Zika virus infection; Use of the nucleic acid molecule according to claim 5 in the preparation of a drug for treating Japanese encephalitis virus and / or Zika virus infection; Use of the vector according to claim 6 in the preparation of a drug for treating Japanese encephalitis virus and / or Zika virus infection; Use of the host cell according to claim 7 in the preparation of a medicament for treating Japanese encephalitis virus and / or Zika virus infection; Use of the pharmaceutical composition according to claim 8 in the preparation of a medicament for treating Japanese encephalitis virus and / or Zika virus infection.
Citation Information
Patent Citations
Monoclonal antibody targeting at Zika virus envelop protein conserved epitope and application thereof
CN109081868A
Japanese encephalitis virus antibody 2G1 and application thereof
CN114621343A
Monoclonal antibody for inhibiting Zika virus infection and application thereof
CN116655785A
Anti-Zika virus monoclonal antibody and application thereof
CN117551189A
